

May 29, 2026

To

BSE Limited,
Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,
Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: OUTCOME OF THE 97TH BOARD MEETING.

Ref: Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held on May 29, 2026, have inter-alia considered and approved the following:

- i. Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, as recommended by the Audit Committee.**

In this regard, we are enclosing herewith a copy of the following:

- ✚ Audited Standalone Financial Statements for the quarter and year ended March 31, 2026.
- ✚ Audited Consolidated Financial Statements for the quarter and year ended March 31, 2026.
- ✚ Statement of Assets & Liabilities and Cash-flow statement.
- ✚ Auditor's Report for Standalone and Consolidated Financial Statements.

- ii. Recommendation of dividend of ₹1.50/- (15%) per equity share of ₹10/- face value, for the year 2025-26, subject to the approval of the Shareholders at the ensuing 20th Annual General Meeting of the Company. AGM date, Book closure dates and the Record date for the purpose of payment of dividend will be announced in the due course.**

- iii. Declaration regarding unmodified opinion by Statutory Auditors of the Company.**

We hereby confirm that M/s Rambabu & Co., Statutory Auditors of the Company have issued Audit Report on standalone and consolidated annual financial results of the Company for the year ended March 31, 2026, with unmodified opinion.

In this regard, a declaration from Chief Financial Officer of the Company is enclosed herewith.



Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)

Page 1 of 4

Registered & Corporate Office: Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad – 500 096, Telangana, India.

Tel: +91-40-6628 8888 | CIN - L74930TG2006PLC050223 | info@haleoslabs.com | www.haleoslabs.com

iv. Related Party Transactions for the half year ended March 31, 2026.

In this regard, enclosed herewith an excerpt of Related Party Transactions for the half year ended March 31, 2026, pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026.

v. Resignation of Mrs. Sundaramma Patibandla (DIN: 02366355) as Independent Director.

Mrs. Sundaramma has tendered her resignation from the position of Independent Director of the Company, with effect from the close of business hours on May 29, 2026.

Please note that a detailed report pursuant to sub-para 7 of para "A" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026, will be submitted separately, within the prescribed timeline.

vi. Reconstitution of Sub-Committees.

In lieu of aforesaid resignation of Mrs. Sundaramma, The Board has duly reconstituted the Audit Committee, Nomination & Remuneration Committee and Stakeholders' Relationship Committee, in accordance with applicable regulatory requirements.

vii. Reappointment of Mrs. Sudeepthi Gopineedi (DIN: 09102540) as Whole-time Director of the Company for a further period of 5 (five) consecutive years w.e.f. Sept 2, 2026, subject to approval of Shareholders.

Please note that a detailed report pursuant to sub-para 7 of para "A" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026, will be submitted separately, within the prescribed timeline.

viii. Approval of overall Managerial Remuneration payable to Executive Director(s).

Pursuant to Regulation 17(6)(e) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, subject to approval of Shareholders.



ix. Conducting of Postal Ballot by way of remote e-voting facility only, to obtain following approval of the shareholder of the Company, Notice of Postal Ballot shall be circulated at a later stage, in compliance with the statutory timelines.

- ✚ Approval of reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director of the Company, for a further period of 5 (five) years.
- ✚ Approval for payment of managerial remuneration to Executive Directors pursuant to Regulation 17(6)(e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- ✚ Approval of material Related Party Transactions of the Company for the year 2026-27.
- ✚ Approval of material Related Party Transactions of the Material Subsidiary of the Company for the year 2026-27.

Company will send Postal Ballot Notice by email to all its members who have registered their email addresses with the Company or depository / depository participants and the communication of assent / dissent of the members will only take place through the remote e-voting system.

x. Appointment / Reappointment of following Auditors of the Company:

- ✚ **Appointment of M/s. Suryanarayana & Suresh, Chartered Accountants [Firm Regt no. 006631S] as Statutory Auditors of the Company for a period of 5 (five) years** pursuant to the provisions of Section 139 of the Companies Act, 2013, subject to the approval of the Shareholders at the ensuing 20th Annual General Meeting of the Company.
- ✚ **Reappointment of M/s Annapragada & Co. (Formerly known as "Harshitha Annapragada & Co.") Cost Accountant (FRN: 006031) as Cost Auditors of the Company for the year 2026-27** pursuant to Section 148 of the Companies Act, 2013, remuneration shall be subject to the approval of the Shareholders at the ensuing 20th Annual General Meeting of the Company.

Please note that a detailed report pursuant to sub-para 7 of para "A" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026, will be submitted separately, within the prescribed timeline.



xi. Contact Details of Key Managerial Personnel(s), pursuant to Regulation 30 (5) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

In furtherance to our earlier intimation dated March 30, 2026, we are submitting the contact details of the Key Managerial Personnel of the Company who have been jointly and / or severally authorized by the Board of Directors of the Company for determining the materiality of any event or information and for the purpose of making the necessary disclosures to the Stock Exchanges.

Sl. No.	Name and Designation of the KMP	Contact details
1)	Mr. TVVSN Murthy [Managing Director]	☎: 9849498899 ✉: murthy@haleoslabs.com
2)	Mr. N. Rajendra Prasad [Chief Financial Officer]	☎: 8374455501 ✉: rajendra@haleoslabs.com
3)	Mr. Trupti Ranjan Mohanty [Company Secretary]	☎: 9861129909 ✉: cs@haleoslabs.com

The above information is also available on the website of the Company www.haleoslabs.com

The meeting of the Board commenced at 2.45 pm and concluded at 3.45 pm.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")

Trupti Ranjan Mohanty

Company Secretary

ICSI memb. no. F13407



HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Standalone Statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Year Ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue From Operations	6,338.42	8,071.91	8,542.78	30,098.96	33,337.10
2	Other Income	96.92	7.84	219.95	142.11	394.56
3	Total Revenue	6,435.34	8,079.75	8,762.73	30,241.07	33,731.66
4	Expenses					
	(a) Cost of Materials Consumed	3,302.37	3,872.67	3,831.70	14,557.49	16,156.07
	(b) Changes in Inventories	(733.80)	(21.45)	585.57	(650.99)	468.60
	(c) Manufacturing Expenses	1,214.04	1,495.52	1,410.36	5,571.54	5,554.59
	(d) Employee Benefits Expense	1,206.07	1,246.18	1,245.54	4,939.27	4,577.67
	(e) Finance Cost	133.68	145.96	184.16	603.42	788.07
	(f) Depreciation and Amortization Expense	265.55	269.09	262.10	1,066.40	1,025.55
	(g) Other Expenses	729.66	323.01	909.89	1,634.83	2,157.00
	Total Expenses - (a to g)	6,117.58	7,330.98	8,429.32	27,721.96	30,727.55
5	Profit Before Tax (3-4)	317.76	748.77	333.41	2,519.11	3,004.11
6	Tax Expenses					
	(1) (i) Current Tax	(75.00)	200.00	100.00	550.00	900.00
	(ii) Relating to Earlier Year	(17.82)	-	-	(17.82)	(18.87)
	(2) Deferred Tax	187.12	8.09	(34.10)	209.25	(14.10)
	Total Tax Expenses	94.30	208.09	65.90	741.43	867.03
7	Net Profit / (Loss) for the Period (5-6)	223.46	540.68	267.51	1,777.68	2,137.08
8	Other Comprehensive Income (OCI):					
	Items that will not be reclassified to profit or Loss:					
	Remeasurement of post-employment benefit obligations	7.35	1.28	56.54	11.03	4.25
	Income Tax effect on the above	2.14	0.37	16.46	3.21	1.24
		5.21	0.91	40.08	7.81	3.01
9	Total Comprehensive Income for the period (7+8)	228.67	541.59	307.59	1,785.49	2,140.09
10	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	7.39	17.88	8.85	58.80	70.69
11	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33
12	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					19,415.22

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri

DIN: 00465198

Managing Director

Standalone Audited Statement of Assets and Liabilities as at 31st March, 2026

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		31.03.2026 (Audited)	31.03.2025 (Audited)
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	18,861.20	14,841.33
	(b) Right-of-use Assets	114.91	177.59
	(c) Capital Work-in-Progress	130.07	39.60
	(d) Intangible Assets	2.24	4.43
	(e) Financial Assets:		
	(i) Investments	2,323.17	2,323.17
	(ii) Other Financial Assets	281.50	278.32
	(f) Other Non-Current Assets	450.20	387.73
	Sub Total :Non-Current Assets	22,163.29	18,052.17
2	Current Assets		
	(a) Inventories	6,981.30	6,058.39
	(b) Financial Assets		
	(i) Trade Receivables	5,426.43	6,452.63
	(ii) Cash and Cash Equivalents	39.89	40.13
	(iii) Bank Balances (Other than (ii) above)	116.09	100.52
	(c) Other Current Assets	5,454.18	5,110.49
	(d) Current Tax Asset (Net)	152.93	16.79
	Sub Total : Current Assets	18,170.82	17,778.95
	TOTAL ASSETS	40,334.11	35,831.12
B	EQUITY AND LIABILITIES		
1	Equity:		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	21,155.36	19,415.22
	Sub-Total -Shareholders' funds	21,457.69	19,717.55
	Liabilities:		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	3,518.19	1,731.06
	(ii) Lease Liabilities	80.97	173.92
	(b) Provisions	403.28	419.68
	(c) Deferred Tax Liabilities (net)	1,571.85	1,359.39
	Sub-Total -Non-Current Liabilities	5,574.29	3,684.05
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,792.61	6,186.19
	(ii) Lease Liabilities	87.59	65.47
	(iii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	81.85	79.32
	(b) Dues to Creditors other than Micro & Small Enterprises	5,297.47	4,519.18
	(iv) Other Financial Liabilities	1,243.38	1,100.90
	(b) Provisions	184.70	159.40
	(c) Other Current Liabilities	614.53	319.06
	Sub-Total - Current Liabilities	13,302.13	12,429.52
	TOTAL - EQUITY AND LIABILITIES	40,334.11	35,831.12

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director

HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)

Standalone Statement of Cash Flow for the Year Ended 31st March, 2026

(All amounts Rupees in Lakhs, unless otherwise stated)

Particulars	For the Year ended 31st March, 2026	For the Year ended 31st March, 2025
A Cash Flow from Operating Activities		
Profit Before Income Tax	2,519.11	3,004.11
Adjustments for:		
Depreciation and amortisation expense	1,066.40	1,025.55
Interest Income classified as Investing Cash Flow	(7.30)	(6.53)
Allowance for Doubtful Debts	(39.63)	505.99
Interest on Non Current Borrowings	181.94	310.17
Provision for Employee Benefits	19.92	18.07
Term Loan Processing Fee	(4.51)	3.54
Loss on Sale of Assets	0.12	2.84
Profit on Sale of Assets.	-	(5.94)
Interest on Leased Premises	23.71	31.14
	3,759.76	4,888.94
Change in Operating Assets and Liabilities		
(Increase)/Decrease in Trade Receivables	1,065.83	(2,023.93)
(Increase)/Decrease in Inventories	(922.92)	1,400.48
Increase/(Decrease) in Trade Payables	780.82	(355.27)
(Increase)/Decrease in Other Non Current Financial Assets	(3.17)	(7.52)
(Increase)/Decrease in Other Non Current Asset	(62.48)	(116.18)
(Increase)/Decrease in Other Current Financial Assets	(0.31)	(0.10)
(Increase)/Decrease in Other Current Asset	(343.69)	(94.56)
(Increase) Decrease in Prepaid Taxes	(18.33)	(140.03)
Increase/(Decrease) in Other Current Financial Liabilities	(57.95)	128.04
Increase/(Decrease) in Other Current Liabilities	295.47	(26.64)
	733.28	(1,235.69)
Cash generated from Operations	4,493.04	3,653.24
Income Tax Paid	(650.00)	(850.00)
Net Cash Inflow from Operating Activities "A"	3,843.04	2,803.24
B Cash flows from Investing Activities		
Purchase for Property, Plant and Equipment	(4,924.47)	(1,408.65)
Proceeds from sale of Property, Plant and Equipment	4.52	33.63
Margin Money Deposits	(15.20)	(7.87)
Interest Received on Margin Money Deposit	7.25	6.28
Net Cash Outflow from Investing Activities "B"	(4,927.90)	(1,376.61)
C Cash flows from Financing Activities		
Proceeds from Long Term Borrowings	3,114.20	35.42
Repayment of Long Term Borrowings	(1,140.35)	(1,364.86)
Proceeds from Short Term Borrowings	(575.78)	370.25
Repayment of Lease Liability	(70.84)	(61.86)
Interest paid	(197.26)	(353.60)
Dividend paid to company's shareholders	(45.35)	(45.35)
Net Cash (Outflow) from Financing Activities "C"	1,084.62	(1,420.00)
Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)	(0.24)	6.64
Cash and Cash Equivalents at the beginning of the Financial Year	40.13	33.49
Cash and Cash Equivalents at End of the Year	39.89	40.13

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director

Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 29th May, 2026 and have been approved by the Board of Directors at its meeting held on 29th May, 2026. The statutory auditors of the Company have carried out the audit for the year ended 31st March, 2026 and issued an unmodified report thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The figures for the current quarter and the corresponding quarter of the previous year are the balancing figures between the audited figures of the full financial years of 2025-26 and 2024-25 and year to date figures published up to 31st December 2025 and 31st December 2024 respectively.
- 4 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company is in compliance with the basic wages criteria as prescribed under New Labour Codes for its employees and also for contract workforce. In view of this and based on the best information available and consistent with the guidance issued by the Institute of Chartered Accountants of India, the management is of the view, that no further provision is required.
- 5 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad
Date : 29-05-2026

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director



RAMBABU & CO.,
CHARTERED ACCOUNTANTS

Independent Auditor's report on the audit of annual standalone financial results of Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited) under regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

To
The Board of Directors of
Haleos Labs Limited
(Formerly known as SMS Lifesciences India Limited)

Opinion

We have audited the accompanying Statement of Standalone Financial Results of Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited) ('the Company') for the year ended March 31, 2026 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations) and both included in the Statement.

In our opinion and to the best of our information and according to the explanations given to us, Standalone Financial Results for the year ended March 31, 2026:

- a. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS 34") prescribed under section 133 of the Companies Act 2013, ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit of this Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the independence requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We



believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

a) Audit of the Standalone Financial Results for the year ended March 31,2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all




relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the Standalone Financial Results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subjected to limited review by us. Our opinion on the Statement is not modified in respect of this matter.

Place: Hyderabad
Date: 29-05-2026

For Rambabu & Co.,
Chartered Accountants
Reg. No.002976S



G V L Prasad
Partner
M.No. 026548



UDIN: 26026548QLGZZR1072

HALEOS LABS LIMITED
(Formerly known as SMS Lifesciences India Limited)
(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096
Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Consolidated Statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Year Ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue From Operations	7,513.91	9,478.31	8,911.24	33,379.45	34,472.35
2	Other Income	201.49	18.34	233.94	243.34	486.01
3	Total Revenue	7,715.40	9,496.65	9,145.18	33,622.79	34,958.36
4	Expenses					
	(a) Cost of Materials Consumed	3,585.99	4,408.42	3,207.00	14,669.42	14,690.76
	(b) Changes in Inventories	(497.77)	(111.86)	663.17	(818.45)	415.21
	(c) Manufacturing Expenses	1,508.02	1,752.02	1,694.54	6,642.58	6,555.05
	(d) Employee Benefits Expense	1,616.59	1,669.65	1,646.96	6,538.25	5,953.78
	(e) Finance Cost	142.04	154.43	203.42	644.52	871.25
	(f) Depreciation and Amortization Expense	384.89	390.99	379.84	1,546.88	1,499.67
	(g) Other Expenses	885.09	355.24	957.40	1,879.95	2,353.65
	Total Expenses - (a to g)	7,624.85	8,618.88	8,752.33	31,103.15	32,339.37
5	Profit Before Tax (3-4)	90.55	877.77	392.85	2,519.64	2,618.99
6	Tax Expenses					
	(1) (i) Current Tax	(86.00)	210.00	100.00	570.00	900.00
	(ii) Relating to Earlier Year	(17.82)	-	-	(17.82)	(18.86)
	(2) Mat Credit Entitlement	11.00	(10.00)	-	(20.00)	-
	(3) Deferred Tax	148.97	12.88	(55.42)	207.42	(135.39)
		56.16	212.88	44.58	739.61	745.75
7	Net Profit / (Loss) for the Period / Year (5-6)	34.40	664.89	348.27	1,780.03	1,873.24
8	Other Comprehensive Income/(Loss) (OCI):					
	Items that will not be reclassified to statement of Profit & Loss					
	Remeasurement of post-employment benefit obligations	6.39	5.82	75.40	15.52	17.87
	Income Tax effect on the above	(1.89)	(1.55)	(21.37)	(4.38)	(4.78)
		4.50	4.27	54.03	11.14	13.09
9	Total comprehensive Income for the period/year (7+8)	38.90	669.16	402.30	1,791.17	1,886.33
10	Profit for the year attributable to:					
	Equity holders of the parent	43.57	661.68	297.28	1,731.20	2,010.90
	Non-controlling interest	(9.17)	3.21	50.99	48.83	(137.66)
11	Total comprehensive income for the year attributable to:					
	Equity holders of the parent	48.35	664.61	345.73	1,738.95	2,019.96
	Non-controlling interest	(9.45)	4.55	56.57	52.22	(133.63)
12	Earning Per Equity Share of Rs.10/- each					
	Basic / Diluted (not annualised)	1.44	21.89	9.83	57.26	66.51
13	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33
14	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					19,353.70

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director

Consolidated Statement of Assets and Liabilities as at 31st March, 2026

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		31.03.2026 (Audited)	31.03.2025 (Audited)
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	26,654.18	23,002.41
	(b) Right-of-use Assets	114.91	177.60
	(c) Capital Work-in-Progress	1,042.21	39.59
	(d) Intangible Assets	2.82	5.15
	(e) Financial Assets:		
	(i) Investments	3.61	3.61
	(ii) Other Financial Assets	340.62	325.65
	(f) Other Non-Current Assets	971.94	387.73
	Sub Total :Non-Current Assets	29,130.29	23,941.74
2	Current Assets		
	(a) Inventories	7,982.42	6,739.79
	(b) Financial Assets		
	(i) Trade Receivables	6,133.93	6,878.71
	(ii) Cash and Cash Equivalents	120.84	50.29
	(iii) Bank Balances (Other than (ii) above)	116.09	100.52
	(c) Other Current Assets	1,777.38	1,265.31
	(d) Current Tax Assets (Net)	179.89	22.75
	Sub Total : Current Assets	16,310.55	15,057.37
	TOTAL ASSETS	45,440.84	38,999.11
B	EQUITY AND LIABILITIES		
1	Equity:		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	21,052.45	19,353.70
	Equity Attributable to Share Holders of the company	21,354.78	19,656.03
	Non Cotroling Interest	1,600.83	1,548.61
	Sub-Total -Shareholders' funds	22,955.61	21,204.64
	Liabilities:		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	4,995.79	1,826.79
	(ii) Lease Liabilities	80.96	173.92
	(b) Provisions	493.36	513.25
	(c) Deferred Tax Liabilities (Net)	1,287.37	1,073.76
	Sub-Total -Non-Current Liabilities	6,857.48	3,587.72
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,889.46	6,574.67
	(ii) Lease Liabilities	87.59	65.47
	(iii) Trade Payables:		
	(a) Trade Payables - Micro & Small Enterprises	104.59	120.36
	(b) Trade Payables - otherthan Micro & Small Enterprises	6,036.02	5,206.62
	(iv) Other Financial Liabilities	1,707.38	1,301.07
	(b) Provisions	188.89	162.05
	(c) Other Current Liabilities	1,613.82	776.51
	(d) Current Tax Liabilities (Net)	-	-
	Sub-Total - Current Liabilities	15,627.75	14,206.75
	TOTAL - EQUITY AND LIABILITIES	45,440.84	38,999.11

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director

HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)

Consolidated Statement of Cash Flow for the Year Ended 31st March, 2026.

(All amounts Rupees in lakhs , unless otherwise stated)

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
A Cash Flow from Operating Activities		
Profit Before Income Tax	2,519.64	2,618.99
Adjustments for:		
Depreciation and amortisation expense	1,546.89	1,499.67
Interest Income classified as Investing Cash Flows	(7.30)	(6.53)
Allowance for Doubtful Debts	(39.63)	505.99
Interest on Non Current Borrowings	217.84	387.40
Provision for Employee Benefits	29.41	53.10
Term Loan Processing Fee	(3.40)	4.65
Profit on Sale of Assets	-	(5.94)
Loss on Sale of Assets	0.12	2.84
Interest On Leased Premises	23.71	31.14
	4,287.28	5,091.30
Change in Operating Assets and Liabilities		
(Increase)/Decrease in Trade Receivables	784.41	(2,249.66)
(Increase)/Decrease in Inventories	(1,242.64)	1,381.26
Increase/(Decrease) in Trade Payables	914.82	(562.78)
(Increase)/Decrease in Other Non Current Financial Assets	(14.97)	(11.86)
(Increase)/Decrease in Other Non Current Asset	(584.21)	(114.39)
(Increase)/Decrease in Other Current Financial Assets	(0.31)	(0.10)
(Increase)/Decrease in Other Current Asset	(4,429.00)	(3,863.22)
(Increase) Decrease in Prepaid Taxes	(39.32)	(134.82)
Increase/(Decrease) in Other Current Financial Liabilities	(57.95)	128.04
Increase/(Decrease) in Other Current Liabilities	4,754.24	4,591.72
	85.07	(835.81)
Cash generated from Operations	4,372.35	4,255.49
Income Taxes Paid	(650.00)	(850.00)
Net Cash Inflow from Operating Activities "A"	3,722.35	3,405.49
B Cash flows from Investing Activities		
Purchase for Property, Plant and Equipment	(5,786.21)	(1,534.86)
Proceeds from sale of Property, Plant and Equipment	4.52	36.66
Margin Money Deposits	(15.20)	(7.87)
Interest Received on Margin Money Deposit	7.25	6.28
Net Cash Outflow from Investing Activities "B"	(5,789.64)	(1,499.79)
C Cash flows from Financing Activities		
Proceeds from Long Term Borrowings	4,591.80	35.42
Repayment of Long Term Borrowings	(1,528.83)	(1,780.00)
Proceeds from Short Term Borrowings	(575.78)	370.25
Repayment of Lease Liability	(70.84)	(61.86)
Interest paid	(233.16)	(430.82)
Dividend paid to company's shareholders	(45.35)	(45.35)
Net Cash (Outflow) from Financing Activities "C"	2,137.84	(1,912.36)
Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)	70.55	(6.66)
Cash and Cash Equivalents at the beginning of the Financial Year	50.29	56.95
Cash and Cash Equivalents at End of the Year	120.84	50.29

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
 DIN: 00466199
 Managing Director

Notes:

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 29th May, 2026 and have been approved by the Board of Directors at its meeting held on 29th May, 2026. The statutory auditors of the Company have carried out the audit for the year ended 31st March, 2026 and issued an unmodified report thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The figures for the current quarter and the corresponding quarter of the previous year are the balancing figures between the audited figures of the full financial years of 2025-26 and 2024-25 and year to date figures published up to 31st December 2025 and 31st December 2024 respectively.
- 4 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Group is in compliance with the basic wages criteria as prescribed under New Labour Codes for its employees and also for contract workforce. In view of this and based on the best information available and consistent with the guidance issued by the Institute of Chartered Accountants of India, the management is of the view, that no further provision is required.
- 5 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary.
- 6 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
DIN: 00465198
Managing Director

Place: Hyderabad
Date : 29-05-2026



RAMBABU & CO.,

CHARTERED ACCOUNTANTS

Independent Auditor's report on the audit of annual consolidated financial results of Haleos Labs Limited (Formerly Known as SMS Lifesciences India Limited) under regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

To
The Board of Directors of
Haleos Labs Limited
(Formerly known as SMS Lifesciences India Limited)

Opinion

We have audited the accompanying consolidated annual financial results of Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited) (hereinafter referred to as the holding Company) and its subsidiary (Holding Company and its subsidiary together referred to as the Group) for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations).

In our opinion and to the best of our information and according to the explanations given to us, the consolidated financial Results for the year ended March 31, 2026:

- (i) includes the share of profit/(loss) of the following subsidiary
M/s. Mahi Drugs Private Limited
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Group for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit of this Consolidated Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the



Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the independence requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of



assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Consolidated Financial Results of the Company to express an opinion on the Consolidated Financial Results.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in



evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other matters


The consolidated financial results includes the audited financial statements/ financial results of subsidiary namely Mahi Drugs Private Limited which have been audited by us whose financial statements / financial results reflect total assets of Rs. 11,854.74 lakhs as at 31 March 2026 total revenue of Rs. 6,019.89 lakhs, total net profit after tax of Rs. 122.08 Lakhs and total comprehensive profit of Rs. 130.55 lakhs for the year ended 31 March 2026.

The Statement includes the Consolidated Financial Results for the quarter ended 31 March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our opinion on the Statement is not modified in respect of this matter.


Place: Hyderabad

Date: 29.05.2026

For Rambabu & Co.,
Chartered Accountants
Reg. No.002976S



GVL Prasad
Partner
M. No. 026548



UDIN: 26026548YEGWBL6187S

S.No	Details of the Party (listed entity / subsidiary) entering in to the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Ref - Note 1)	Value of the related party transaction ratified by the audit committee	Value of transaction during reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments										
	Name	PAN (Ref - Note 3)	Name	PAN (Ref - Note 3)	Relationship of the counterparty with the listed entity or its subsidiary					Opening Balance	Closing Balance	Nature of indebtedness	Cost	Tenure	Nature (loans/advance/inter-corporate deposit/investment)	Interest rate (%)	Tenure	Secured/Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)						
1	Haleos Labs Limited (formerly known as SMS Lifesciences India Limited)		Purogene Labs Private Limited		Enterprises over which Directors or their relatives exercise significant influence	Purchases of Goods & Services	4,000.00	-	1,218.95	206.93	-96.88	-	-	-	-	-	-	-							
2						Sale of Goods & Services	3,000.00	-	135.39	-	-	-	-	-	-	-	-	-	-	-	-				
3						Rent received	10.00	-	2.12	-	-	-	-	-	-	-	-	-	-	-	-				
4			Mahl Drugs Private Limited			Material Subsidiary	Material Subsidiary	Purchases of Goods & Services	5,500.00	-	786.65	3,587.95	3,959.37	-	-	-	-	-	-	-					
5								Sale of Goods & Services	3,000.00	-	196.24	-	-	-	-	-	-	-	-	-	-	-	-		
6								Rent received	10.00	-	3.19	-	-	-	-	-	-	-	-	-	-	-	-		
7			SMS Pharmaceuticals Ltd				Other Related Party	Other Related Party	Purchases of Goods & Services	510.00	-	-	-	-	-	-	-	-	-	-	-				
8									Sale of Goods & Services	3,000.00	-	619.39	888.40	437.76	-	-	-	-	-	-	-	-	-	-	
9			ChemWerth Inc, USA					Other Related Party	Other Related Party	Purchases of Goods & Services	500.00	-	-	-	-	-	-	-	-	-	-	-			
10										Sale of Goods & Services	2,000.00	-	0.88	-100.00	-99.12	-	-	-	-	-	-	-	-	-	-
11										Receipt of business advance	1,500.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12			TVVSN Murthy					-	-	Key Management Personnel	-	-	-	99.21	7.20	7.50	-	-	-	-	-	-	-		
13			T V Praveen					-	-	Executive Director	-	-	-	52.35	6.10	5.60	-	-	-	-	-	-	-		
14			G Sudeepthi					-	-	Whole Time Director	-	-	-	14.91	1.61	1.61	-	-	-	-	-	-	-		
15	Mahl Drugs Private Limited		Purogene Labs Private Limited	Enterprises over which Directors or their relatives exercise significant influence				Purchases of Goods & Services	500.00	-	13.22	-	-	-	-	-	-	-	-	-					
16								Sale of Goods & Services	500.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
17			ChemWerth Inc, USA	Other Related Party				Purchases of Goods & Services	500.00	-	-	-	-	-	-	-	-	-	-	-	-	-			
18					Sale of Goods & Services			3,500.00	-	-347.83	-347.83	-	-	-	-	-	-	-	-	-	-	-			
19			SMS Pharmaceuticals Ltd	Other Related Party	Receipt of business advance			1,500.00	-	-	-	-	-	-	-	-	-	-	-	-	-				
20					Purchases of Goods & Services			35.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
21	Sale of Goods & Services		500.00	-	54.65	61.65		54.60	-	-	-	-	-	-	-	-	-	-	-						
Total										3,197.15															

Note:
 1. The value of the related party transactions denotes the amount approved by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company and the subsidiary, as the case may be, for the year 2025-26.
 2. Purchase / Sale of Goods & Services were approved individually by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company. However, for reporting purpose the same has been dubbed.
 3. As per the guidance note for disclosure of Related Party Transactions dated 25.04.2022, issued by the Stock Exchanges, since the Company is filing this disclosure in PDF format, the PAN details are not to be included in the disclosure. *(XBRL filed separately along with PAN)*
 4. Aforesaid transactions with related parties are in the ordinary course of business and in arm's length basis.
 5. Sitting fees paid to Independent Directors & Remuneration paid to KMPs are not disclosed pursuant to SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024.
 6. Remuneration paid to Directors were individual approved by Audit / Board / Shareholders during respective appointment / reappointment.

For Haleos Labs Limited

Veera Venkata Satyanarayana Murthy Talluri
 DIN: 00465198
 Managing Director

DECLARATION REGARDING UNMODIFIED OPINION BY STATUTORY AUDITORS

Regulation 33(3)(d) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

I, N Rajendra Prasad, Chief Financial Officer of Haleos Labs Limited (formerly known as "SMS Lifesciences India Limited"), hereby declare that the Statutory Auditors of the Company i.e. M/s Rambabu & Co., Chartered Accountants (Registration No. 002976S) have issued Audit Report(s) with an unmodified opinion on audited (Standalone and Consolidated) financial results of the Company for the quarter and year ended March 31, 2026, as approved by the Board of Directors at its meeting held today i.e. May 29, 2026.

This declaration is given in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

This is for your information and records.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")



N Rajendra Prasad
Chief Financial officer



Date: 29.05.2026

Place: Hyderabad

Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)

Registered & Corporate Office: Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad - 500 096, Telangana, India.

Tel: +91-40-6628 8888 | CIN - L74930TG2006PLC050223 | info@haleoslabs.com | www.haleoslabs.com